Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate (original) (raw)

Arthritis care & research, 2015

Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study

2019

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis

RMD open, 2016

Tofacitinib with Methotrexate in Third-Line Treatment of Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3 Trial

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial

Arthritis & rheumatology (Hoboken, N.J.), 2018

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study

Shrikant Wagh

Arthritis & Rheumatology, 2019

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Irmgadt Sariego

Lancet (London, England), 2017

Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study

Federico Navarro-sarabia

Clinical and experimental rheumatology, 2018

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses

Rheumatology and therapy, 2018

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry

Dimitrios Pappas

Rheumatology and Therapy, 2020

Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study

Yoshiya Tanaka

Rheumatology (Oxford, England), 2017

Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial

Arthritis Care & Research, 2016

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

Jonathan French

Arthritis & Rheumatism, 2012

Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study

Mauro Keiserman

Arthritis & Rheumatology

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)

Yoshiya Tanaka

Annals of the rheumatic diseases, 2016

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Cristiano Moura

Arthritis research & therapy, 2018

Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study

Sławomir Jeka

Rheumatology

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Federico Navarro-sarabia

Annals of the Rheumatic Diseases, 2013

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

Rheumatology (Oxford, England), 2016

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

Mark Genovese

Arthritis research & therapy, 2016

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

International Journal of Rheumatic Diseases, 2016

The 6-month drug survival rate in patients with rheumatoid arthritis treated with tofacitinib

Burak Öz

Annals of Medical Research, 2021

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

Shahin Jamal

ACR Open Rheumatology, 2019

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Mark Genovese

Annals of the Rheumatic Diseases, 2010

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

New England Journal of Medicine, 2012

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Arthritis Research & Therapy, 2015

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis

Alomgir Hossain 191-29-235

The Cochrane database of systematic reviews, 2016

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis

Rheumatology and Therapy

Risk Factors Associated With Non-Respondence to Methotrexate in Rheumatoid Arthritis Patients

Daniya Haroon

Cureus, 2021

Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia

Geoffrey Littlejohn

Clinical Rheumatology, 2021

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial

Arthritis Care & Research, 2017

Sustained Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Patients with Rheumatoid Arthritis

Jorge Morales Torres

The Journal of Rheumatology, 2013

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial

Ricardo Blanco

Annals of the rheumatic diseases, 2017